Tsumura & Co

Tsumura & Co maintains a strong liquidity position, with a current ratio of 4.78 and cash and equivalents of ¥73.23 billion, which provides a buffer against short-term obligations. The company's debt-to-equity ratio of 0.24 indicates a conservative capital structure, with long-term debt of ¥70.80 billion compared to total equity of ¥300.53 billion. Free cash flow of ¥6.88 billion supports operational flexibility and potential reinvestment. The company's profitability metrics are in line with industry norms, with a return on equity of 10.79% and a return on assets of 6.98%. These figures suggest that Tsumura is effectively utilizing its equity and asset base to generate returns, though the ROE is modest compared to high-growth pharmaceutical peers. Tsumura's revenue is concentrated in its core pharmaceutical business, with no disclosed geographic diversification beyond Japan. The company's exposure to a single market increases its vulnerability to domestic regulatory and economic shifts. Looking ahead, Tsumura's revenue is projected to grow modestly, with no significant changes in the near-term outlook. The company's capital expenditure of ¥29.79 billion indicates ongoing investment in infrastructure and R&D, which is typical for a pharmaceutical firm. The risk assessment for Tsumura is favorable, with low liquidity and dilution risks. No immediate filing-based flags were detected, and the company's capital structure remains stable. The absence of dilution risk is supported by the fact that basic and diluted shares outstanding are equal, indicating no near-term dilution pressure. Recent events, including analyst estimates and price targets, suggest a cautious outlook from the market. The mean price target of ¥4,375 and median of ¥4,150 reflect a range of expectations, with three "hold" recommendations and two "buy" ratings.